#Moonshot Monday – Titan Pharmaceuticals
Here at SFE we’re always looking for the sneaky way to get the biggest bang for your buck. Mostly that involves swinging for the fences and this is no exception. Moonshot Monday is a weekly series where we pick a long shot stock which we think has a great chance to rocket to the moon in the coming months. We’re not looking for consistent returns, diversified investments, or other bull that you look for in your 401k. This here be riverboat gambling, the sneakiest kind.
This week, we’re injecting ourselves into the wild world of biotech.
March 12, 2018 – Titan Pharmaceuticals (TTNP) – $0.9899
What do they do?
From Yahoo Finance, “Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases.” Most important in there are “proprietary long-term drug delivery technology” and “develops”. They are actively seeking new ways to make use of what they alone own.
What’s sneaky about this pick?
They’re currently developing a drug to help fight Parkinson’s Disease, and that drug is in the very early stages: “Phase 1/2 treatment has commenced – noted October 11, 2017. Data from first patient cohort due 1H 2018.” As with all biotechs, every phase “hurdle” that the drug passes will see the price jump accordingly. Think of this as your time to get in on the ground floor.
What are our prospects?
Remember that this whole section is about riverboat gambling? Well biotechs are only slightly better than playing the lottery. Nine times out of ten, you’ll be ripping up your worthless ticket, but boy when that tenth time is a winner…
The play – High risk, high reward. $50 in now with the hopes that we can get at least 10x on that investment if things go well. See you at the top!